Vaccines for the elderly.
The aging of the human population is posing serious challenges to research and to public health authorities in order to prevent diseases that more frequently affect the elderly, a portion of the population that will increase more and more in the coming years. While some vaccines exist and are used in the elderly to effectively fight against some infections (e.g. influenza, pneumococci, varicella-zoster virus, diphtheria, and tetanus), still a lot of work remains to be done to better adapt these vaccines and to develop new ones for this age group. The prevention of infectious diseases affecting the elderly can be successful only through a holistic approach. This approach will aim at the following: (1) a deeper understanding of the mechanisms leading to the senescence of the immune system, (2) a better and broader use of vaccines recommended for the elderly, (3) the use of vaccines currently considered only for other age groups and (4) actively priming the population when they are immunological competent, before the physiological waning of immune responsiveness may affect the beneficial effects of vaccination.
Novartis Vaccines, Research Center, Siena, Italy.
Giuseppe
G
Del Giudice
Birgit
B
Weinberger
Beatrix
B
Grubeck-Loebenstein
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000276:immunology*; D005260:Female; D005853:Geriatrics; D006801:Humans; D007108:Immune Tolerance; D007121:Immunocompetence; D007252:Influenza Vaccines / Q000627:therapeutic use; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D008297:Male; D014611:Vaccination / Q000379:methods; D014612:Vaccines / Q000627:therapeutic use*
D007252:Influenza Vaccines; D014612:Vaccines